Oct 29, 1977

Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards

Lancet
N ZainalG D Summers

Abstract

Patients with acute myocardial infarction admitted to open wards of three hospitals were given either oral disopyramide (100 mg four times daily) or matching placebo, prophylactically, for seven days. The drug was associated with a significant reduction in mortality (p = 0-0025) and in incidence of extension of infarction (p = 0-01), ventricular fibrillation (p = 0-05), and ventricular tachycardia (p = 0-01). Disopyramide was not associated with any particular complication or side-effect. Unitl information is available to the contrary, oral disopyramide should be given for the first seven days after myocardial infarction to all patients not managed in an intensive-care unit.

Mentioned in this Paper

Ventricular Fibrillation
Disopyramide Oral Product
Pyridines
Heart Block
Disopyramide
Hospitalization
Disopyramide, L-Tartrate, (S)-isomer
Myocardial Infarction
Acute Disease
Drug Evaluation

About this Paper

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.